Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma
Status:
Terminated
Trial end date:
2018-11-12
Target enrollment:
Participant gender:
Summary
This is a study with the purpose of studying the safety and efficacy of the study drug
Atezolizumab in patients with relapsed or refractory Hodgkin lymphoma (HL). Atezolizumab
could shrink cancer but it could also cause side effects. This study will also test any good
and bad effects the study drug. Other aims include studying biomarkers that will help
researchers understand how the drug works.